Publication-Ready Oncology Research: A Complete Biostatistical Framework for UAE Hospital Research Teams
Five advanced statistical methods applied to a 600-patient oncology cohort. demonstrating the analytical framework that gets clinical research published in peer-reviewed journals.
Simulated Data for Demonstration
All datasets, statistical outputs, and visualizations use synthetically generated data for portfolio and educational purposes. Results are illustrative of advanced biostatistical methodology.
At a Glance
Who This Is For
Hospital research teams, clinical investigators, oncology departments, and academic researchers in the UAE preparing studies for peer-reviewed publication. who need advanced survival analysis executed at international journal standard.
What This Demonstrates
A five-method analytical framework. Kaplan-Meier estimation, multivariable Cox regression, competing risks analysis, time-varying covariate modelling, and linear mixed-effects modelling. applied sequentially to a 600-patient cohort with 10-year follow-up. The complete biostatistics toolkit for rigorous oncology research.
Why It Matters for Your Research
Peer reviewers reject oncology papers most frequently for statistical reasons. inadequate handling of competing risks, baseline-only biomarker models, missing proportional hazards validation. This framework addresses every one of these proactively, before submission.
The Research Context
UAE hospitals are generating increasingly rich clinical datasets. oncology registries, longitudinal patient follow-up data, biomarker measurement series, treatment outcome records. The clinical expertise to generate this data exists within hospital research teams. What is frequently missing is the statistical methodology to turn it into publication-ready research.
The gap is specific and consistent: clinical teams know what questions they want to answer. They do not always have access to the advanced biostatistical methods. competing risks analysis, time-varying covariates, longitudinal mixed-effects modelling. that peer-reviewed journals in oncology now expect as standard.
The consequence is research that stalls before publication, or reaches peer review and is returned with statistical revision requests that delay publication by months.
This case study demonstrates the complete analytical framework StatZen Analytics applies to oncology survival research. using a synthetic dataset of 600 early-stage oncology patients with 10-year follow-up. showing exactly what becomes possible when clinical data meets rigorous biostatistical methodology.
Why Standard Statistical Approaches Are Not Enough
Oncology research has specific statistical challenges that standard approaches handle poorly. Each challenge has a methodological solution. and using the wrong method produces biased estimates that peer reviewers will identify and reject.
| The Challenge | Why Standard Methods Fail | The Correct Approach |
|---|---|---|
| Patients can die from causes other than cancer. cardiovascular disease, other malignancies, complications | Standard Cox regression treats non-cancer deaths as censored observations. as if the patient simply left the study. This systematically overestimates cancer-specific mortality, particularly in older cohorts | Competing risks analysis (Fine-Gray model) explicitly accounts for the fact that a patient who dies of cardiovascular disease can no longer die of cancer. producing accurate absolute risk estimates |
| Biomarkers like CA 15-3 change dynamically during treatment. rising before recurrence, falling with successful therapy | Baseline-only Cox models fix biomarker values at the start of follow-up and ignore subsequent changes. This misses the dynamic information that often most strongly predicts outcomes | Time-varying covariate analysis splits follow-up into intervals and updates biomarker values at each measurement. capturing the predictive signal in biomarker trajectories rather than just baseline values |
| Repeated measurements from the same patient over time are correlated. not independent observations | Standard linear regression assumes all observations are independent. Applying it to repeated measures underestimates standard errors and inflates statistical significance. producing findings that will not replicate | Linear mixed-effects models account for within-patient correlation through random effects. allowing each patient to have their own baseline and trajectory while estimating population-level treatment effects correctly |
| Survival curves need to be compared across groups while controlling for confounding factors | Kaplan-Meier curves show unadjusted survival differences. they cannot control for age, stage, grade, and treatment simultaneously | Multivariable Cox proportional hazards regression adjusts for all covariates simultaneously. producing hazard ratios that represent the independent effect of each factor |
The methodological standard peer reviewers expect:
High-impact oncology journals now expect competing risks analysis whenever non-cancer deaths are a realistic outcome, time-varying analysis when biomarkers are measured longitudinally, and proportional hazards assumption testing for every Cox model. Submitting without these. or using standard Cox regression when Fine-Gray is appropriate. is one of the most common reasons for statistical rejection at the revision stage.
THE ANALYSIS
Five Methods. Five Clinical Questions
Each method in this framework was chosen to answer a specific clinical question that the other methods cannot. They are applied sequentially. each building on the previous. to produce a complete, multi-layered picture of survival, prognosis, treatment efficacy, and biomarker dynamics.
Problem Statement & Research Context
Oncology research demands sophisticated statistical approaches to answer complex clinical questions about survival, prognosis, and treatment efficacy. Traditional single-method analyses often provide incomplete insights, failing to account for competing risks, time-varying biomarker dynamics, or repeated measurements inherent in longitudinal cancer care.
Key Challenges:
- Survival analyses must distinguish cancer-specific mortality from competing causes (e.g., cardiovascular death), yet standard Cox regression treats these as censored events, leading to biased estimates
- Baseline-only models ignore dynamic biomarker changes (e.g., rising tumor markers) that often precede clinical events
- Treatment efficacy cannot be fully assessed without examining longitudinal biomarker trajectories and differential response patterns
- Multivariable risk models require careful attention to proportional hazards assumptions, collinearity, and model discrimination
This case study addresses these challenges by integrating five complementary statistical methodsinto a comprehensive analytical framework, demonstrating how methodological triangulation provides more robust clinical insights than any single approach alone.
Executive Summary
This case study demonstrates a comprehensive survival and longitudinal analysis of early-stage oncology patients using a synthetic dataset of 600 patients. The analysis employs a sequential approach with five advanced statistical methods to address specific clinical questions that simpler methods cannot answer.
The core objective is to provide a robust and multi-faceted understanding of prognostic factors, treatment effects, and disease monitoring markers. Each method builds upon the previous, creating a complete analytical framework for oncology research.
Sequential Analytical Approach
Kaplan-Meier Estimation
Non-parametric survival curves stratified by clinical factors
Cox Proportional Hazards Regression
Multivariable modeling to identify independent risk factors
Competing Risks Analysis
Accounts for death from other causes to prevent bias
Time-varying Covariate Analysis
Captures dynamic biomarker changes during follow-up
Linear Mixed-Effects Modeling
Longitudinal biomarker trajectories by treatment group
Table 1: Five Analytical Methods and Their Clinical Purpose
| Method | Clinical Question Answered | R Package |
|---|---|---|
| Kaplan-Meier + Log-rank | How does survival differ by stage, receptor status, and treatment? | survival, survminer |
| Cox Proportional Hazards | Which clinical factors independently predict OS and DFS, and by how much? | survival, rms, broom |
| Competing Risks (Fine-Gray) | Does Stage II increase cancer-specific death after accounting for death from other causes? | cmprsk |
| Time-varying Cox | Does rising CA 15-3 during follow-up predict subsequent death? | survival (tstart/tstop format) |
| Linear Mixed Effects (LME) | How does CA 15-3 change over time, and does trajectory differ by treatment? | lme4, nlme |
Study Design & Data
2.1 Data Source
- Synthetic dataset (n=600) simulating real-world early-stage oncology registry
- Captures clinical, pathological, treatment characteristics, biomarker measurements, and survival follow-up
- All data synthetically generated for portfolio and educational purposes
- Reproducible with
set.seed(2026)
2.2 Dataset Structure
Three linked datasets used across the five analyses:
| Dataset | Rows × Cols | Description |
|---|---|---|
| Master Dataset | 600 × 18 | One row per patient. Baseline characteristics, OS, DFS, and event type. |
| Time-varying Dataset | ~1,800 rows | Counting process format (tstart/tstop). One interval per biomarker measurement window. |
| Longitudinal Dataset | ~2,400 rows | Long format. Repeated CA 15-3 measurements at 0, 3, 6, 12, 24 months per patient. |
2.3 Complete Variable Dictionary
| Variable | Type | Description & Clinical Relevance |
|---|---|---|
| age | Continuous | Age at diagnosis (years). Range 25–80, mean ~52. |
| stage | Categorical | Cancer Stage I or II. 45% Stage I, 55% Stage II in this cohort. |
| grade | Ordinal | Histological grade G1/G2/G3. Higher grade = more aggressive tumour biology. |
| er_status | Binary | Receptor status (Positive/Negative). Positive status associated with better prognosis. |
| her2_status | Binary | HER2 receptor status. Positive status associated with more aggressive disease. |
| treatment | Categorical | Treatment received: Hormone / Chemo / Chemo+Hormone / None. |
| nodes_pos | Count | Number of positive lymph nodes. Strong prognostic indicator. |
| tumor_size | Continuous | Tumour size in cm at diagnosis. |
| ca153_base | Continuous | Baseline CA 15-3 serum marker (U/mL). Tumour marker used for treatment monitoring. |
| os_time / os_event | Survival | Overall survival time (months) and event indicator (1=death, 0=censored). Max 10 years. |
3. Kaplan-Meier Survival Analysis
3.1 Method Overview
Kaplan-Meier estimation is a non-parametric method for estimating the survival function from lifetime data. It handles censored observations (patients lost to follow-up or alive at study end) by calculating the probability of surviving past each event time, multiplying these conditional probabilities to produce survival curves.
3.2 Statistical Testing
Log-rank test compares survival curves between groups. A p-value < 0.05 indicates a statistically significant difference in survival distributions. The test is sensitive to differences occurring throughout follow-up.
Figure 1: Overall Survival by Cancer Stage
- Stage I
- Stage II
Log-rank test: χ² = 38.5, p < 0.001. Median OS: Stage I = 86.4 months, Stage II = 52.1 months
Figure 2: Disease-Free Survival by Receptor Status
- ER Negative
- ER Positive
Log-rank test: χ² = 42.1, p < 0.001. Median DFS: ER+ = 78.2 months, ER- = 38.7 months
Figure 3: Overall Survival by Treatment Group
- Chemo
- Chemo+Hormone
- Hormone
- None
Log-rank test: χ² = 42.8 (df=3), p < 0.001. Combined therapy shows superior survival
Table 4: Kaplan-Meier Analyses Summary
| Figure | Comparison | Test | p-value | Key Metrics |
|---|---|---|---|---|
| Fig 1 | OS by Stage I vs II | Log-rank | < 0.001 | Median OS: I=86.4mo, II=52.1mo; 5yr OS: I=64%, II=34% |
| Fig 2 | DFS by ER Status | Log-rank | < 0.001 | Median DFS: ER+=78.2mo, ER-=38.7mo; 3yr DFS: ER+=76%, ER-=49% |
| Fig 3 | OS by Treatment (4-way) | Log-rank (χ²=42.8, df=3) | < 0.001 | Chemo+Hormone superior; None shows poorest survival |
Clinical Interpretation: Stage II disease, ER-negative status, and lack of treatment are associated with significantly worse survival outcomes. The survival curves demonstrate clear separation, with differences emerging within 12-18 months and persisting throughout follow-up.
4. Cox Proportional Hazards Model
4.1 Method Overview
The Cox proportional hazards model is a semi-parametric regression approach that models the hazard function as:
The baseline hazard h₀(t) is unspecified, making it flexible. The model estimates Hazard Ratios (HRs): an HR of 1.5 means a 50% higher instantaneous risk of the event compared to the reference group.
4.2 Proportional Hazards Assumption
The model assumes hazard ratios remain constant over time. This is tested using cox.zph(). A non-significant p-value (p > 0.05) supports the proportional hazards assumption. Visual inspection via Schoenfeld residual plots should show horizontal trends.
Figure 4: Multivariable Cox Model - Forest Plot of Hazard Ratios
Green bars indicate protective factors (HR < 1), red bars indicate increased risk (HR > 1)
Table 5: Cox Proportional Hazards Multivariable Results
| Variable | HR | 95% CI | p-value | Interpretation |
|---|---|---|---|---|
| Stage II (vs I) | 2.34 | 1.76–3.12 | < 0.001 | 134% increase in hazard |
| Age (per year) | 1.03 | 1.01–1.05 | 0.002 | 3% increase in hazard |
| Grade G3 (vs G1) | 1.89 | 1.34–2.67 | < 0.001 | 89% increase in hazard |
| ER Positive (vs Negative) | 0.62 | 0.47–0.82 | < 0.001 | 38% reduction in hazard |
| HER2 Positive (vs Negative) | 1.45 | 1.12–1.88 | 0.005 | 45% increase in hazard |
| Chemo+Hormone (vs None) | 0.48 | 0.34–0.68 | < 0.001 | 52% reduction in hazard |
| Nodes positive (per node) | 1.18 | 1.10–1.27 | < 0.001 | 18% increase in hazard |
| Tumour size (per cm) | 1.12 | 1.05–1.20 | < 0.001 | 12% increase in hazard |
| C-statistic (OS model) | 0.780 | |||
Clinical Interpretation: After adjusting for all covariates, Stage II disease (HR=2.34), Grade 3 tumours (HR=1.89), HER2-positive status (HR=1.45), and higher lymph node burden (HR=1.18 per node) independently increase mortality risk. Combined chemo-hormone therapy provides substantial protection (HR=0.48, 52% risk reduction). The model demonstrates good discrimination (C-statistic=0.78).
5. Competing Risks Analysis
5.1 Why Competing Risks?
Standard Cox regression treats deaths from other causes as censored, assuming they are uninformative. This can overestimate cancer-specific mortality, particularly in older cohorts where competing causes (cardiovascular disease, other cancers) are common.
Competing risks analysis explicitly acknowledges that experiencing one event (e.g., cardiovascular death) precludes experiencing the other (cancer death), providing more accurate absolute risk estimates.
Table 6: Cause-Specific Cox vs Fine-Gray. When to Use Each
| Approach | What It Estimates | When to Use |
|---|---|---|
| Cause-specific Cox | Hazard of cancer death among those still alive and event-free | Understanding biological/aetiological effect of a covariate on cancer death specifically |
| Fine-Gray | Sub-distribution Hazard based on cumulative incidence function (CIF) | Predicting absolute risk and informing clinical decisions about who needs preventive intervention |
Figure 5: Cumulative Incidence Functions by Stage
- Stage I - Cancer Death
- Stage I - Other Cause
- Stage II - Cancer Death
- Stage II - Other Cause
Solid lines: cancer-specific death. Dashed lines: other-cause death. Stage II shows higher cancer-specific CIF.
Clinical Interpretation: At 10 years, Stage II patients have a 76% cumulative incidence of cancer death vs 52% for Stage I. Other-cause mortality contributes ~21-26% across stages, highlighting the importance of not treating these deaths as simple censoring events. Fine-Gray analysis (sHR for Stage II = 2.18, p<0.001) accounts for competing risks in risk prediction.
6. Time-Varying Covariate Analysis
6.1 The Problem with Baseline-Only Models
Standard Cox models assume covariates are fixed at baseline. However, biomarkers like CA 15-3 change dynamically during follow-up, and rising levels often precede disease recurrence or death.
Time-varying covariate analysis captures these dynamic changes by splitting follow-up into intervals, updating covariate values at each measurement. This uses the counting process format (tstart/tstop).
Table 7: Counting Process Format. Example Patient
Patient 001 had rising CA 15-3, died at month 38:
| Patient | tstart | tstop | CA 15-3 | event |
|---|---|---|---|---|
| 001 | 0 | 6 | 22.1 | 0 |
| 001 | 6 | 12 | 25.4 | 0 |
| 001 | 12 | 38 | 41.7 | 1 |
Figure 6: CA 15-3 Trajectories by Risk Group
- High Risk (Rapid Rise)
- Low Risk (Stable)
- Medium Risk (Moderate Rise)
HR for CA 15-3 (time-varying Cox model): 1.04 per U/mL (95% CI: 1.02–1.06, p < 0.001)
Clinical Interpretation: Each 1 U/mL increase in CA 15-3 during follow-up is associated with a 4% increase in subsequent mortality hazard (adjusted for baseline characteristics). Patients with rapidly rising CA 15-3 (red line) demonstrate the highest risk, validating CA 15-3 as a dynamic monitoring marker independent of baseline clinical factors.
7. Linear Mixed-Effects Model. Longitudinal CA 15-3
7.1 Why Mixed Effects for Longitudinal Data?
Repeated measurements from the same patient are correlated. Standard linear regression assumes independence, leading to underestimated standard errors and inflated significance.
Linear mixed-effects (LME) models account for within-patient correlation by including random effects(random intercepts and slopes), allowing each patient to have their own baseline and trajectory while estimating population-level (fixed) effects.
Table 8: Model Hierarchy. Sequential Building
| Model | Formula | Purpose |
|---|---|---|
| M0 | ca153 ~ 1 + (1|id) | Null / Intercept only. Estimate ICC (Intraclass Correlation Coefficient) |
| M1 | ca153 ~ time + (1|id) | Random intercept + time. Average CA 15-3 trend |
| M2 | ca153 ~ time*treatment + age + stage + er_status + (time|id) | Full model. Treatment × time interaction. Random intercept & slope |
| M3 | AR(1) residuals (nlme) + corAR1(form = ~time|id) | Test if residuals within a patient are autocorrelated over time |
7.2 Treatment × Time Interaction
The key question: Do treatment groups show different CA 15-3 trajectories?
- Negative
time:treatmentCombinedcoefficient → CA 15-3 declines faster in combined therapy patients - Positive
time:treatmentNonecoefficient → Untreated patients show rising CA 15-3
Figure 7: Population-Level Predicted CA 15-3 Trajectories by Treatment
- Chemo
- Chemo+Hormone
- Hormone
- None
Treatment × Time interaction: F = 18.4, p < 0.001. Combined therapy shows steepest decline.
Clinical Interpretation: CA 15-3 declines by ~60% over 24 months in combined therapy patients (from 119 to 48 U/mL) but increases by ~25% in untreated patients (from 122 to 152 U/mL). The significant treatment×time interaction (p<0.001) confirms differential biomarker response, validating treatment efficacy and supporting CA 15-3 as a monitoring tool.
8. Integrated Results & Clinical Narrative
This comprehensive analysis combines findings from all five methods to construct a coherent clinical story. Each method contributes a distinct layer of evidence, creating a robust analytical framework:
| Analysis | Clinical Answer |
|---|---|
| KM. OS by Stage | Stage II patients have meaningfully lower 5- and 10-year OS. Survival curves diverge from ~18 months. Log-rank p quantifies significance. |
| KM. DFS by ER Status | ER-positive patients show longer disease-free intervals, consistent with hormone therapy benefit. ER status is the single strongest prognostic binary marker. |
| Cox PH. Multivariable OS | After adjusting for all covariates, Stage II, Grade 3, HER2+, and positive nodes independently increase hazard. Chemo+Hormone significantly reduces hazard vs no treatment. |
| Competing Risks | CIF analysis shows the proportion of deaths attributable to cancer vs other causes. Fine-Gray sHR for Stage II on cancer death may differ from Cox HR. illustrating the risk of misclassifying competing events as censored. |
| Time-varying Cox (CA 15-3) | Rising CA 15-3 during follow-up is an independent predictor of subsequent death, over and above baseline clinical characteristics. This validates CA 15-3 as a dynamic monitoring marker. |
| LME. CA 15-3 Trajectories | CA 15-3 declines over 24 months in patients receiving Chemo+Hormone, rises in untreated patients. The treatment × time interaction is statistically significant, confirming differential biomarker response. |
Methodological Triangulation
This case study demonstrates the value of methodological triangulation. using multiple complementary approaches to answer complex clinical questions. No single method provides the complete picture: Kaplan-Meier offers intuitive survival visualization, Cox models identify independent risk factors, competing risks prevent bias, time-varying analysis captures dynamic biomarker changes, and LME models confirm differential treatment response. Together, they form a complete analytical skillset for modern biostatistics and clinical research.
9. Limitations
Data Limitations
- • Synthetic data: true clinical effect sizes may differ
- • Missing variables: Ki-67, BRCA status, compliance, radiotherapy
- • Sample size: n=600 with ~40% events
Methodological Assumptions
- • PH assumption: if violated, requires time-stratified models
- • Informative censoring: assumed non-informative
- • LME linearity: assumes linear trajectories
Clinical Generalizability
- • Single-institution cohort structure
- • Early-stage focus: may not generalize to advanced disease
- • Treatment protocols: specific to simulated guidelines
Statistical Considerations
- • Multiple testing: no adjustment applied
- • Model selection: potential overfitting with many predictors
- • Competing risks: adequate events per category required
9. R Package Reference
| Package | Analysis | Key Functions |
|---|---|---|
| survival | KM, Cox PH, TV Cox | Surv(), survfit(), coxph(), cox.zph() |
| survminer | KM plots | ggsurvplot(), ggcoxzph() |
| cmprsk | Competing risks | cuminc(), crr() |
| lme4 | Mixed effects | lmer(), fixef(), ranef(), VarCorr() |
| nlme | LME with correlation | lme(), corAR1() |
| broom | Tidy model output | tidy(), glance(), augment() |
| rms | Discrimination & calibration | cph(), val.surv(), calibrate() |
What This Framework Delivers for UAE Hospital Research Teams
Statistical methodology is not the goal. publication is. Here is what this analytical framework produces that moves research from data to journal:
A Methods Section That Passes Peer Review
Every analysis in this framework is documented with the statistical tests applied, assumptions checked, R packages used, and interpretation language required for a Methods section that meets international journal standards. The proportional hazards assumption is tested. The competing risks rationale is stated. The mixed-effects model hierarchy is documented. These are the details reviewers look for. and the details that separate a revision request from an acceptance.
Competing Risks Handled Correctly From the Start
The Fine-Gray model for competing risks is not a niche technique. it is now expected in any oncology survival analysis where non-cancer deaths are a realistic outcome. Applying standard Cox regression in this setting produces biased estimates that reviewers at oncology journals will identify. Building competing risks analysis into the framework from the start eliminates one of the most common reasons for statistical rejection.
Biomarker Dynamics Captured. Not Just Baseline Values
CA 15-3 as a time-varying covariate produced an independent mortality hazard ratio of 1.04 per U/mL (95% CI: 1.02–1.06, p<0.001). a finding invisible to baseline-only models. If your research involves biomarkers measured at multiple timepoints, this is the method that extracts the full predictive value of your longitudinal data rather than reducing it to a single baseline measurement.
Treatment Efficacy Confirmed at the Biomarker Level
The mixed-effects model confirmed that CA 15-3 declines by approximately 60% over 24 months in combined therapy patients. and rises by approximately 25% in untreated patients. The treatment x time interaction (F=18.4, p<0.001) validates the biomarker as a treatment monitoring tool, not just a prognostic marker. This level of evidence. biomarker trajectory analysis by treatment group. is what elevates a clinical paper from descriptive to mechanistically informative.
Services Used in This Engagement
Research & Academic Support
Study design and statistical methodology, data analysis using R, SPSS, STATA, and Python, manuscript statistical review for journal submission, results interpretation for non-technical co-authors.
Clinical & Healthcare Analytics
Patient outcome analysis and benchmarking, survival analysis, longitudinal data modelling, clinical data audit and quality assessment.
Predictive Modelling & Advanced Analytics
Multivariable risk modelling, competing risks analysis, time-varying covariate modelling, model discrimination and calibration assessment.
Publications & Research Support
Systematic review and meta-analysis support, manuscript statistical review, results interpretation in journal-ready language, statistical methodology documentation for Methods sections.
Conclusion
This case study demonstrates a comprehensive, reproducible analytical framework for oncology research, progressing from intuitive survival visualization through increasingly sophisticated methods that capture competing risks, dynamic biomarker changes, and differential treatment responses.
Each method builds upon the previous, addressing limitations and adding clinical nuance. The result is a complete analytical pipeline suitable for health data science, medical statistics consultancy, and academic biostatistics portfolios.
Is Your Research Team Ready to Publish?
If your hospital has clinical data and a research question but lacks the statistical capacity to execute at peer review standard. that is exactly the gap we fill. Whether you need a complete analytical framework from scratch, a methodology review before submission, or statistical support at the revision stage. we work with your data and your clinical team to get the research to publication.
Book a free 30-minute consultation. Bring your research question, your dataset structure, and your target journal. We will tell you exactly what the analysis requires and what the timeline looks like.